Maraviroc Completed Phase 4 Trials for Inflammation / HIV Infection With Other Conditions / Cardiovascular Risk / Atherosclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03402815Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.